Cambrian Bio records a positive human trial with its AMPK Activator drug, ATX-304

Scientists may have finally found a way to safely restore AMPK function in humans, a milestone many researchers in the aging biology field have pursued for almost 30 years. In a release on Monday, biotech company Cambrian Bio reported positive Phase 1b results for ATX-304, a clinical-stage drug designed to activate the AMPK metabolic pathway....